On the relationship between human papilloma virus vaccine and autoimmune diseases

Autoimmunity Reviews

Volumn 13, Issue 7, 2014, Pages 736-741

  Pellegrino, Paolo ^a   Carnovale, Carla ^a   Pozzi, Marco ^b   Antoniazzi, Stefania ^c   Perrone, Valentina ^a   Salvati, Dionigi ^a   Gentili, Marta ^a   Brusadelli, Tatiana ^a   Clementi, Emilio ^a,b   Radice, Sonia ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b SCIENTIFIC INSTITUTE   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Acute disseminated encephalomyelitis; Autoimmunity diseases; Human papilloma virus vaccine; Juvenile idiopathic arthritis; Multiple sclerosis; Rheumatoid arthritis

Indexed keywords

WART VIRUS VACCINE;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; AUTOIMMUNE DISEASE; DEMYELINATING DISEASE; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNIZATION; INFLAMMATORY BOWEL DISEASE; JUVENILE RHEUMATOID ARTHRITIS; MULTIPLE SCLEROSIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; AUTOIMMUNE DISEASES; FEMALE; IMMUNOLOGY; INCIDENCE; PAPILLOMAVIRUS INFECTIONS; VACCINATION;

AUTOIMMUNE DISEASES; FEMALE; HUMANS; INCIDENCE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VACCINATION;

EID: 84898881700     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.01.054     Document Type: Review

References (69)

1. Harper D.M., Vierthaler S.L., Santee J.A. Review of Gardasil. J Vaccines Vaccin Nov 23 2010, 1(107).
2. Harper D.M., Williams K.B. Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies. Discov Med Jul 2010, 10(50):7-17.
3. Harper D.M., Vierthaler S.L. Next generation cancer protection: the bivalent HPV vaccine for females. ISRN Obstet Gynecol 2011, 2011:457204.
4. Harper D.M. HPV vaccine against HPV infection and disease in males. N Engl J Med Jun 2 2011, 364(22):2164.
5. Harper D.M., Vierthaler S.L. Who should be targeted for vaccination against anal cancer?. Lancet Oncol Sep 2011, 12(9):828-829.
6. Sarojini N.B., Srinivasan S., Madhavi Y., et al. The HPV vaccine: science, ethics and regulation. Econ Polit Weekly 2010, 45(48):27-34.
7. Verdenius I., Groner J.A., Harper D.M. Cross protection against HPV might prevent type replacement. Lancet Infect Dis Mar 2013, 13(3):195.
8. Harper D.M., Nieminen P., Paavonen J., Lehtinen M. Cervical cancer incidence can increase despite HPV vaccination. Lancet Infect Dis Sep 2010, 10(9):594-595. [author reply 5].
9. Harper D.M. Currently approved prophylactic HPV vaccines. Expert Rev Vaccines Dec 2009, 8(12):1663-1679.
10. Harper D.M. Current prophylactic HPV vaccines and gynecologic premalignancies. Curr Opin Obstet Gynecol Dec 2009, 21(6):457-464.
11. Harper D.M. Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health. Public Health Genomics 2009, 12(5-6):319-330.
12. Tomljenovic L., Spinosa J.P., Shaw C.A. Human papillomavirus (HPV) vaccines as an option for preventing cervical malignancies: (how) effective and safe?. Curr Pharm Des 2013, 19(8):1466-1487.
13. Gerhardus A., Razum O. A long story made too short: surrogate variables and the communication of HPV vaccine trial results. J Epidemiol Community Health 2010, 64(5):377-378.
14. Macartney K.K., Chiu C., Georgousakis M., Brotherton J.M. Safety of human papillomavirus vaccines: a review. Drug Saf 2013, 36:393-412.
15. Siegrist C.A., Lewis E.M., Eskola J., Evans S.J., Black S.B. Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis J 2007, 26:979-984.
16. Slade B.A., Leidel L., Vellozzi C., Woo E.J., Hua W., Sutherland A., et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009, 19:750-757.
17. Shoenfeld Y., Aron-Maor A. Vaccination and autoimmunity-'vaccinosis': a dangerous liaison. J Autoimmun 2000, 14:1-10.
18. Salemi S., D'Amelio R. Could autoimmunity be induced by vaccination?. Int Rev Immunol 2010, 29:247-269.
19. Orbach H., Agmon-Levin N., Zandman-Goddard G. Vaccines and autoimmune diseases of the adult. Discov Med 2010, 9:90-97.
20. Schäffer V., Wimmer S., Rotaru I., et al. HPV vaccine: a cornerstone of female health a possible cause of ADEM?. J Neurol 2008, 255:1818-1820.
21. Wildemann B., Jarius S., Hartmann M., et al. Acute disseminated encephalomyelitis following vaccination against human papilloma virus. Neurology 2009, 72:2132-2133.
22. Mendoza Plasencia Z., González López M., Fernández Sanfiel M.L. Muñiz Montes Acute disseminated encephalomyelitis with tumefactive lesions after vaccination against human papillomavirus. Neurologia 2010, 25:58-59.
23. Pellegrino P., Carnovale C., Perrone V., Antoniazzi S., Pozzi M., Clementi E., et al. Can HPV immunisation cause ADEM? Two case reports and literature review. Mult Scler Aug 22 2013, PMID: 23970503, [Epub ahead of print].
24. DiMario F.J., Hajjar M., Ciesielski T. A 16-year-old girl with bilateral visual loss and left hemiparesis following an immunization against human papilloma virus. J Child Neurol 2010, 25:321-327.
25. Pellegrino P., Carnovale C., Perrone V., Pozzi M., Antoniazzi S., Clementi E., et al. Acute disseminated encephalomyelitis onset: evaluation based on vaccine adverse events reporting systems. PLoS One 2013, 8:e77766. 10.1371/journal.pone.0077766.
26. Menge T., Cree B., Saleh A., Waterboer T., Berthele A., Kalluri S.R., et al. Neuromyelitis optica following human papillomavirus vaccination. Neurology 2012, 79:285-287.
27. Wingerchuk D.M., Lennon V.A., Lucchinetti C.F., Pittock S.J., Weinshenker B.G. The spectrum of neuromyelitis optica. Lancet Neurol 2007, 6:805-815.
28. Farrell R.A. Comment: human papillomavirus vaccination, induced autoimmunity, and neuromyelitis optica. Neurology 2012, 79:287.
29. Herroelen L., de Keyser J., Ebinger G. Central-nervous-system demyelination after immunisation with recombinant hepatitis B vaccine. Lancet 1991, 338:1174-1175.
30. DeStefano F., Verstraeten T., Chen R.T. Hepatitis B vaccine and risk of multiple sclerosis. Expert Rev Vaccines 2002, 4:461-466.
31. Sutton I., Lahoria R., Tan I., Clouston P., Barnett M. CNS demyelination and quadrivalent HPV vaccination. Mult Scler 2009, 15:116-119.
32. Chang J., Campagnolo D., Vollmer T.L., Bomprezzi R. Demyelinating disease and polyvalent human papilloma virus vaccination. J Neurol Neurosurg Psychiatry 2011, 82:1296-1298.
33. Pellegrino P., Carnovale C., Perrone V., Antoniazzi S., Pozzi M., Clementi E., et al. No evidence of a link between multiple sclerosis and the vaccine against the human papillomavirus. Eur J Epidemiol 2013, 28:705-707.
34. Kwong J.C., Vasa P.P., Campitelli M.A., Hawken S., Wilson K., Rosella L.C., et al. Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study. Lancet Infect Dis 2013, 13:769-776.
35. Ojha R.P., Jackson B.E., Tota J.E., Offutt-Powell T.N., Singh K.P., Bae S. Guillain-Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States. Hum Vaccin Immunother 2013, 10:1. PMID: 24013368.
36. Slade B.A., Leidel L., Vellozzi C., Woo E.J., Hua W., Sutherland A., et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009, 302:750-757.
37. Souayah N., Michas-Martin P.A., Nasar A., et al. Guillain-Barre syndrome after Gardasil vaccination: data from Vaccine Adverse Event Reporting System 2006-2009. Vaccine 2011, 29(5):886-889.
38. Slade B.A., Gee J., Broder K.R., Vellozzi C. Comment on the contribution by Souayah et al., "Guillain-Barré syndrome after Gardasil vaccination: data from Vaccine Adverse Event Reporting System 2006-2009". Vaccine Jan 29 2011, 29(5):865-866.
39. Heijstek M.W., de Bruin LM Ott, Bijl M., et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis 2011, 70:1704-1712.
40. Gatto M., Agmon-Levin N., Soriano A., Manna R., Maoz-Segal R., Kivity S., et al. Human papillomavirus vaccine and systemic lupus erythematosus. Clin Rheumatol 2013, 32:1301-1307.
41. Soldevilla H.F., Briones S.F., Navarra S.V. Systemic lupus erythematosus following HPV immunization or infection?. Lupus 2012, 21:158-161.
42. Soybilgic A., Onel K.B., Utset T., Alexander K. Wagner-Weiner L safety and immunogenicity of the quadrivalent HPV vaccine in female systemic lupus erythematosus patients aged 12 to 26years. Pediatr Rheumatol Online J 2013, 11:29.
43. Mok C.C., Ho L.Y., Fong L.S., To C.H. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis 2013, 72:659-664.
44. Pellegrino P., Carnovale C., Perrone V., Salvati D., Gentili M., Antoniazzi S., et al. Human papillomavirus vaccine in patients with systemic lupus erythematosus. Epidemiology 2014, (1):155-156. 10.1097/EDE.0000000000000033.
45. Rojo-Contreras W., Olivas-Flores E.M., Gamez-Nava J.I., Montoya-Fuentes H., Trujillo-Hernandez B., Trujillo X., et al. Cervical human papillomavirus infection in Mexican women with systemic lupus erythematosus or rheumatoid arthritis. Lupus 2012, 21:365-372.
46. Gross K., Combe C., Krüger K., Schattenkirchner M. Arthritis after hepatitis B vaccination. Report of three cases. Scand J Rheumatol 1995, 24:50-52.
47. Pope J.E., Stevens A., Howson W., Bell D.A. The development of rheumatoid arthritis after recombinant hepatitis B vaccination. J Rheumatol 1998, 25:1687-1693.
48. Heijstek M.W., Scherpenisse M., Groot N., Tacke C., Schepp R.M., Buisman A.M., et al. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study. Ann Rheum Dis 2013, 30.
49. Beena J.P. Juvenile idiopathic arthritis: review of the literature and case report. J Dent Child (Chic) 2013, 80:25-30.
50. Kane S., Khatibi B., Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol 2008, 103:631-636.
51. Al-Bawardy B., Fine S., Lafond J., Doran A., Borum M.L. Missing cohort: inflammatory bowel disease patients at increased risk for cervical dysplasia may be undervaccinated for HPV. Inflamm Bowel Dis 2012, 18:797.
52. Jacobson D.L., Bousvaros A., Ashworth L., Carey R., Shrier L.A., Burchett S.K., et al. Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease. Inflamm Bowel Dis 2013, 19:1441-1449.
53. Colafrancesco S., Perricone C., Tomljenovic L., Shoenfeld Y. Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants. Am J Reprod Immunol 2013, 31.
54. Little D.T., Ward H.R. Premature ovarian failure 3years after menarche in a 16-year-old girl following human papillomavirus vaccination. BMJ Case Rep Sep 30 2012, pii: bcr2012006879. 10.1136/bcr-2012-006879.
55. Cerami C., Corbo M., Piccolo G., Iannaccone S. Autoimmune neuromyotonia following human papilloma virus vaccination. Muscle Nerve Mar 2013, 47(3):466-467.
56. Ikeya S., Urano S., Tokura Y. Linear IgA bullous dermatosis following human papillomavirus vaccination. Eur J Dermatol 2012, 22:787-788.
57. Della Corte C., Carlucci A., Francalanci P., Alisi A., Nobili V. Autoimmune hepatitis type 2 following anti-papillomavirus vaccination in a 11-year-old girl. Vaccine 2011, 29:4654-4656.
58. Melo Gomes S., Glover M., Malone M., Brogan P. Vasculitis following HPV immunization. Rheumatology (Oxford) 2013, 52:581-582.
59. Watanabe T., Hashidate H., Hirayama Y., Iinuma Y. Kikuchi-Fujimoto disease following vaccination against human papilloma virus infection and Japanese encephalitis. Eur J Pediatr 2012, 171:1409-1411.
60. Yonee C., et al. Association of acute cerebellar ataxia and human pailloma virus vaccination: a case report. Neuropediatrics 2013, 44:265-267.
61. Katoulis A.C., Liakou A., Bozi E., Theodorakis M., Alevizou A., Zafeiraki A., et al. Erythema multiforme following vaccination for human papillomavirus. Dermatology 2010, 220:60-62.
62. Pugnet G., Ysebaert L., Bagheri H., Montastruc J.L., Laurent G. Immune thrombocytopenic purpura following human papillomavirus vaccination. Vaccine Jun 8 2009, 27(28):3690.
63. Berry P.A., Smith-Laing G. Hepatitis A vaccine associated with autoimmune hepatitis. World J Gastroenterol 2007, 13:2238-2239.
64. Herroelen L., de Keyser J., Ebinger G. Central-nervous-system demyelination after immunisation with recombinant hepatitis B vaccine. Lancet 1991, 1174-1175.
65. Marshall E. A shadow falls on hepatitis B vaccination effort. Science 1998, 31:630-631.
66. DeStefano F., Weintraub E.S., Chen R.T. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology 2005, 64:1317-1318.
67. Guo Y., Shi L., Hong H., Su Z., Fuscoe J., Ning B. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine. Sci China Life Sci 2013, 56:119-124.
68. McCormack M., Alfirevic A., Bourgeois S., Farrell J.J., Kasperavičiute D., et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011, 364:1134-1143.
69. Zhang F.R., Liu H., Irwanto A., Fu X.A., Li Y., Yu G.Q., et al. HLA-B*13:01 and the dapsone hypersensitivity syndrome. N Engl J Med 2013, 369:1620-1628.